PL2568045T3 - Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania - Google Patents

Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania

Info

Publication number
PL2568045T3
PL2568045T3 PL12196192.4T PL12196192T PL2568045T3 PL 2568045 T3 PL2568045 T3 PL 2568045T3 PL 12196192 T PL12196192 T PL 12196192T PL 2568045 T3 PL2568045 T3 PL 2568045T3
Authority
PL
Poland
Prior art keywords
mutant
making
methods
protein coupled
coupled receptors
Prior art date
Application number
PL12196192.4T
Other languages
English (en)
Inventor
Jonathan Richard Heal
Richard Henderson
Christopher Gordon Tate
Malcolm Peter Weir
Original Assignee
Heptares Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Limited filed Critical Heptares Therapeutics Limited
Publication of PL2568045T3 publication Critical patent/PL2568045T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
PL12196192.4T 2007-12-08 2008-12-08 Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania PL2568045T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0724051.8A GB0724051D0 (en) 2007-12-08 2007-12-08 Mutant proteins and methods for producing them

Publications (1)

Publication Number Publication Date
PL2568045T3 true PL2568045T3 (pl) 2024-05-13

Family

ID=38983182

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12196192.4T PL2568045T3 (pl) 2007-12-08 2008-12-08 Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania

Country Status (10)

Country Link
US (1) US8748182B2 (pl)
EP (2) EP2568045B1 (pl)
JP (2) JP2011505800A (pl)
AU (1) AU2008332896B2 (pl)
CA (1) CA2708037C (pl)
DK (1) DK2220229T3 (pl)
ES (1) ES2972473T3 (pl)
GB (2) GB0724051D0 (pl)
PL (1) PL2568045T3 (pl)
WO (1) WO2009071914A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121919B1 (en) 2007-03-22 2012-02-08 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
WO2008068534A2 (en) * 2008-03-05 2008-06-12 Heptares Therapeutics Limited Crystal structure of a betal -adremergi c receptor and uses thereof
GB0910725D0 (en) * 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP3333185A1 (en) * 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
DK2742066T3 (en) 2011-08-10 2018-03-05 Heptares Therapeutics Ltd STABLE PROTEINS
JP6251252B2 (ja) 2012-06-01 2017-12-20 ヘプタレス セラピューティックス リミテッド アッセイ
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
PT2951201T (pt) 2013-01-30 2018-01-09 Univ Brussel Vrije Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos
US9932385B2 (en) 2013-03-15 2018-04-03 Medical Research Council Mutant proteins and methods for their production
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2016070022A1 (en) 2014-10-31 2016-05-06 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
EP3344043A4 (en) * 2015-09-04 2019-07-10 The Scripps Research Institute METHOD FOR IDENTIFYING NEW ANTIBIOTICS AND RELATED COMPOSITIONS
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
WO2017149394A1 (en) 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
AU2017259821B2 (en) 2016-05-04 2024-07-18 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
WO2018150260A1 (en) * 2017-02-16 2018-08-23 Institut Pasteur Method for the identification of mutated proteins having modified thermal stability

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
JP3147916B2 (ja) 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995032425A1 (en) 1994-05-23 1995-11-30 Smithkline Beecham Corporation Encoded combinatorial libraries
US20020028443A1 (en) 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
AU2020497A (en) 1996-03-27 1997-10-17 Susan R. George Receptor and transporter antagonists
WO1997039131A1 (en) 1996-04-15 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
NZ531722A (en) 1999-11-17 2006-06-30 Arena Pharm Inc Endogenous and non-endogenous versions of human G protein-coupled receptors
US7462457B2 (en) 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
EP1353555A2 (en) 2000-10-26 2003-10-22 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
CN1516706A (zh) 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US20070010948A1 (en) 2001-03-30 2007-01-11 Masaji Ishiguro G protein-coupled receptor structural model and a method of designing ligand binding to g protein-coupled receptor by using the structural model
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
JP2005522989A (ja) 2001-10-25 2005-08-04 アステックス テクノロジー リミテッド チトクロムｐ４５０２ｃ９の結晶、その構造、およびその使用
US7115377B2 (en) 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
WO2003091282A1 (fr) 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Mutant a activite ordinaire du recepteur h3 de l'histamine et utilisation correspondante
ES2340475T3 (es) 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated Estructura cristalizada de proteina aurora-2 y sus bolsillos de union.
US7745161B2 (en) 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20050287565A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
US20060188964A1 (en) 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
US20070154947A1 (en) 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
WO2007097820A2 (en) 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2121919B1 (en) * 2007-03-22 2012-02-08 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
WO2008068534A2 (en) * 2008-03-05 2008-06-12 Heptares Therapeutics Limited Crystal structure of a betal -adremergi c receptor and uses thereof
EP2284207B1 (en) * 2008-05-30 2012-07-04 Asahi Glass Company, Limited Hard foam synthetic resin and process for producing the same
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP3333185A1 (en) 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs

Also Published As

Publication number Publication date
AU2008332896B2 (en) 2014-05-08
WO2009071914A3 (en) 2009-10-15
CA2708037A1 (en) 2009-06-11
WO2009071914A2 (en) 2009-06-11
GB2467830B (en) 2013-05-15
GB2467830A (en) 2010-08-18
JP2015133973A (ja) 2015-07-27
ES2972473T3 (es) 2024-06-12
EP2220229A2 (en) 2010-08-25
EP2568045A1 (en) 2013-03-13
AU2008332896A1 (en) 2009-06-11
JP6567291B2 (ja) 2019-08-28
GB201000387D0 (en) 2010-02-24
EP2568045B1 (en) 2024-01-24
GB0724051D0 (en) 2008-01-16
US8748182B2 (en) 2014-06-10
DK2220229T3 (da) 2020-09-07
JP2011505800A (ja) 2011-03-03
EP2220229B1 (en) 2020-06-24
US20110028700A1 (en) 2011-02-03
CA2708037C (en) 2018-09-18

Similar Documents

Publication Publication Date Title
PL2568045T3 (pl) Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania
GB0607196D0 (en) G-protein coupled receptor agonists
GB0720390D0 (en) G-Protein coupled receptor agonists
EP2173174A4 (en) FARNESOID X RECEPTOR AGONISTS
EP2170072A4 (en) Farnesoid X RECEPTOR AGONISTS
GB2469585B (en) Urinal apparatus
EP2650009B8 (en) Screening methods using G-protein coupled receptors and related compositions
GB0720389D0 (en) G-Protein Coupled Receptor Agonists
GB0810309D0 (en) Non-bolt joint structure and method for producing non-bolt joint structure
IL198650A0 (en) Progesterone receptor antagonists
EP2121756A4 (en) ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
IL212545A0 (en) Toll-like receptor 3 antagonists
GB0802474D0 (en) Mutant proteins and methods for selecting them
TWI370107B (en) Novel methods for making and using halosilylgermanes
ZA201005826B (en) Selective agonist of toll-like receptor 3
GB0624237D0 (en) Toilet apparatus
IL205432A0 (en) Method of identigfying safe nmda receptor antagonists
GB0717918D0 (en) Toilet apparatus
GB0725125D0 (en) urinal apparatus
GB2456904B (en) Stable neurotensin receptor mutants
AU2007902971A0 (en) Receptors and related methods and products
GB0720388D0 (en) G-protein coupled receptor agonists
GB0608516D0 (en) Receptor
GB0623853D0 (en) Receptor
GB0623399D0 (en) Receptor